LabStyle Innovations Announces 2014 Third Quarter Results and Provides Business Update
Increasing sales as market penetration of Dario™ grows in the fourth quarter
CAESAREA, Israel, November 14, 2014 /PRNewswire/ — LabStyle Innovations Corp. (OTCQB: DRIO), developer of the Dario™ Diabetes Management Solution, today reported its financial and operational results for the three month period ending September 30, 2014 and provided an update on recent corporate achievements and anticipated milestones for the remainder of 2014 and 2015.
Of particular note, LabStyle reported that:
- Distribution and sales of the Dario™ blood glucose monitoring and diabetes management system (including Dario™ smart meters, test strips and lancets) are scaling up in LabStyle’s initial “soft launch” markets including, in addition to the U.K. and New Zealand, the Netherlands and Australia. Dario™ has been well received with excellent feedback from users. This has resulted in over 25,000 free Dario™ app downloads in the initial launch territories, and a higher than industry average pick up rate, thus indicating the potential to convert downloads to users of Dario™ in an efficient and productive manner.
- LabStyle anticipates recording revenue next quarter and is implementing a strong strategy for growth based on new market penetration, including in Latin American and the Asia Pacific region.
- LabStyle is currently anticipating a potential FDA clearance and U.S. launch of Dario™ by mid-2015. Based on its interactions with the U.S. Food and Drug Administration on its previously announced 510(k) application for Dario™, LabStyle will soon commence a new 300 subject English language User Performance Evaluation in the U.S., which LabStyle views as a promising development towards the FDA clearance.
- LabStyle believes it is demonstrating success in building a strong supportive community of people with diabetes using Dario™ for their diabetes management needs, primarily in the United Kingdom. Early Dario™ adopters have expressed great satisfaction with the product and have experienced enhanced user performance and adherence when using the Dario™ smart meter.
The initial launch of Dario™ has been undertaken on a limited basis as the company conserves resources and evaluates distributor and end-user feedback as it refines its longer term roll out plans. Even on this limited basis, LabStyle made initial shipments to distribution partners amounting to approximately $113,000 during the first nine months of the year, of which $66,000 were in the third quarter. In accordance with U.S. generally accepted accounting principles (GAAP), LabStyle did not formally recognize revenues from such activities. The company expects to recognize initial revenues, which is expected to be derived from recurring orders of test strip cartridges and lancets and, in a small number of select jurisdictions, sales of Dario™ smart meters, during the fourth quarter of 2014 upon receipt of payment from distributors.
Erez Raphael, LabStyle’s President and Chief Executive Officer, stated “We believe that proof of our commercial potential has been demonstrated as we are now selling Dario™ in targeted countries and expanding into new countries in a focused and planned manner. Following our most recent financing in September, we are scaling up production in order to meet demand from our soft launch. We will continue our commercialization efforts for the remainder of 2014 and into 2015 by launching Dario™ in new selected markets as well as accelerating activities seeking to create other potential revenue streams through strategic digital health partnerships”
“In the U.S., we are pleased to report that we have been diligently working with FDA on obtaining clearance for Dario™” continued Mr. Raphael. “This interaction has led us to recently finalize plans for a new U.S. study aimed at evaluating the usability of the Dario™ and its accuracy in the hands of end-users, and we are commencing this study imminently. We view this as a promising development for two reasons. First, we believe this shows that our 510(k) application (which will include the results of this new study) is progressing towards what we have always anticipated would be a positive ultimate outcome. Second, we have a demonstrated track record of performing these types of studies with successful outcomes, both recently in Israel and also in conjunction with our 2013 CE Mark approval of Dario™. As a result, we remain as hopeful as ever that we will achieve U.S. clearance for Dario™. Due to the need for this new study, we are conservatively moving out our anticipated timing for potential clearance from early 2015 to mid-2015.”
During the third quarter of 2014, LabStyle has achieved the following on target milestones as the company continues to implement its global rollout and user acquisition plans for Dario™:
- Received regulatory approval to sell the Dario™ Smart Meter in Australia and Israel.
- Shipped first orders for initial distribution in the Netherlands and generated early sales through an e-commerce website.
- Received a Notice of Allowance from the U.S. Patent and Trademark Office for core patent claims covering the Dario™ smart meter.
- Built a business and marketing strategy for initial sales in Canada together with the company’s Canadian distribution partner.
- Built a strong strategy for Dario™ brand awareness to diabetes professionals, general practitioners and caregivers in order to facilitate patient reimbursement and ease of access to the Dario™ smart meters, test strips and lancets.
- Worked to optimize production of Dario™ smart meters for both Android and iOS smartphone operating systems by enhancing the logistics and shipment process enabling delivery of the Dario™ smart meters, test strips and lancets in a timely and productive manner.
- Launched the Android supported Dario™ smart meter and app. This was a positive addition to the Dario™ community as according to IDC, 80% of the smartphone market is comprised of Android device users.
- Ramped up the product launch in New Zealand and the United Kingdom where positive feedback is being received from users of Dario™. The product launch in Italy has been paused in order to reevaluate the Italian marketing strategy and leverage data accumulated regarding the Italian market.
- The Dario™ app has been downloaded by tens of thousands of users in the markets where available, and LabStyle is implementing its strategy to convert these app users into Dario™ smart meter users.
- Reimbursement for the Dario™ smart meter has been obtained in the initial Dario™ launch markets. Achieving approval for insurance reimbursement allows LabStyle to reach more users through deeper market penetration.
- NHS code received for sales in England, Wales, Scotland and Northern Ireland where Dario™ strips and lancets are available under reimbursement status in all major pharmacies.
Summary of Financial Results
As evidenced by a reduction in expenses as detailed below, LabStyle’s management is working to focus the company’s resources on activities aimed at driving stockholder value.
As of September 30, 2014, LabStyle had had cash, cash equivalents and short-term bank deposits of approximately $4,257,000. LabStyle forecasts such funds will be sufficient to continue its activities into March 2015, and additional financing will be required in order for LabStyle to fund planned operations
Ramp up of manufacturing costs for the third quarter of 2014 were approximately $585,000 compared with none for the third quarter of 2013, and for the first nine months of 2014 were approximately $1,611,000 compared with none for the first nine months of 2013. The increase was due to the commencement of initial commercial sales during March 2014 with first shipments occurring during April 2014.
Research and development expenses for the third quarter of 2014 were approximately $769,000 compared with approximately $1,078,000 for the third quarter of 2013, and for the first nine months of 2014 were approximately $3,209,000 compared with $3,169,000 for the first nine months of 2013. The decrease was mainly due the increased focus in production as well as sales and marketing efforts with relation to our commencement of initial commercial sales offset by increase in our regulation and product localization efforts related to relevant requirement in different jurisdictions.
Marketing and pre-production expenses were approximately $252,000 for the third quarter of 2014 compared with approximately $763,000 for the third quarter of 2013 and approximately $911,000 in the first nine months of 2014 compared with approximately $1,924,000 for the first nine months of 2013. This decrease was mainly due to pre-production costs which were recorded during 2013. During 2014, LabStyle began to ramp up manufacturing and commenced initial shipments to distributors and therefore did not record any additional pre-production costs.
General and administrative expenses for the third quarter of 2014 were approximately $901,000 compared to approximately $1,397,000 for the third quarter of 2013 and approximately $3,047,000 for the first nine months of 2014 compared with approximately $4,817,000 for the first nine months of 2013. The decrease was driven by cost reduction efforts, including a decrease in management compensation, overhead costs and outsourcing consulting expenses, as well as decrease in option compensation driven from decrease in the market value for LabStyle’s common stock, which resulted in fair value decrease of new awards granted during the third quarter of 2014.
Financing expenses for the third quarter of 2014 were mainly driven by approximately $2,606,000 non-cash gain related to the revaluation of warrants offset by approximately $3,124,000 non-cash expense related to common stock consideration granted to the investors from LabStyle’s February 2014 private placement, compared with a loss related to the revaluation of warrants of approximately $192,000 in the third quarter of 2013. Financing expenses for the first nine months of 2014 were mainly driven by an approximately $3,144,000 non-cash gain related to the revaluation of warrants offset by a loss of approximately $533,000 from issuance costs related to warrants in the first nine months of 2014 and by an approximately $3,124,000 non-cash expense related to common stock consideration granted to investors from LabStyle’s February 2014 private placement, compared with a loss related to the revaluation of warrants of approximately $3,992,000 in the first nine months of 2013.
The net loss for the third quarter of 2014 was approximately $6,333,000, or $0.66 per share, compared with a net loss of approximately $3,471,000, or $0.85 per share, for the third quarter of 2013. For the first nine months of 2014 the net loss was approximately $12,571,000, or $2.03 per share, compared with a net loss of approximately $13,985,000, or $3.95 per share, for the first nine months of 2013. Net loss for the three and nine months ended September 30, 2014 included deemed dividend costs related to LabStyle’s September 2014 private placement issuance of convertible preferred stock in the amount of approximately $2,977,000 and approximately $279,000 related to consideration granted to the investors in LabStyle’s February 2014 private placement.
The non-GAAP adjusted loss, as detailed in the table below, for the third quarter of 2014 was approximately $2,081,000, or $0.21 per share, compared with a non-GAAP adjusted loss for the third quarter of 2013 of approximately $2,231,000, or $0.55 per share. The non-GAAP adjusted loss for the first nine months of 2014 was approximately $6,795,000, or $0.10 per share, versus a non-GAAP adjusted loss of approximately $5,728,000, or $1.61 per share, in the corresponding period in 2013.
LabStyle used approximately $6,168,000 in cash to fund operating activities during the first nine months of 2014.
Note on Non-GAAP Measures
Readers should note that LabStyle has, in the schedule below, supplemented its GAAP net income (loss) with a non-GAAP measure of adjusted EBITDA. Management believes that this non-GAAP financial measure provides useful supplemental information to management and investors regarding LabStyle’s performance, facilitates a more meaningful comparison of results for current periods with previous operating results, and assists management in analyzing future trends, making strategic and business decisions and establishing internal budgets and forecasts. A reconciliation of non-GAAP adjusted EBITDA to GAAP net income (loss) in the most directly comparable GAAP measure is provided in the schedule below.
There are limitations in using this non-GAAP financial measure because it is not prepared in accordance with GAAP and may be different from non-GAAP financial measures used by other companies. This non-GAAP financial measure should not be considered in isolation or as a substitute for GAAP financial measures. Investors and potential investors should consider non-GAAP financial measures only in conjunction with the Company’s consolidated financial statements prepared in accordance with GAAP and the reconciliations of the non-GAAP financial measure provided in the schedule below:
|
Unaudited US Dollars in thousands except stock and stock data |
Three months ended September 30, |
Nine months ended September 30, |
||||||
|
2014 |
2013 |
2014 |
2013 |
|||||
|
Net income (loss) as reported |
$ (6,333) |
$ (3,471) |
$ (12,571) |
$ (13,985) |
||||
|
Adjustments: |
||||||||
|
Depreciation |
103 |
264 |
461 |
578 |
||||
|
Revaluation of warrants |
(2,606) |
192 |
(3,144) |
3,992 |
||||
|
Issuance cost related to warrants to investors and service provider |
44 |
– |
533 |
– |
||||
|
Compensation to the February 2014 Investors from Exchange Agreement |
3,124 |
– |
3,124 |
– |
||||
|
Other finance expenses |
8 |
41 |
24 |
83 |
||||
|
Deemed dividend related to exchange agreement |
279 |
– |
279 |
– |
||||
|
Deemed dividend related to Series A Preferred Stock |
2,977 |
– |
2,977 |
– |
||||
|
EBITDA |
$ (2,404) |
$ (2,974) |
$ (8,317) |
$ (9,332) |
||||
|
Stock-based compensation |
323 |
743 |
1,522 |
2,593 |
||||
|
Expenses related to Issuance of common stock and warrants to service provider |
– |
– |
– |
1,011 |
||||
|
Non-GAAP adjusted EBITDA |
$ (2,081) |
$ (2,231) |
$ (6,795) |
$ (5,728) |
||||
|
Weighted average number of common stock used in computing basic and diluted net loss per share |
9,610,160 |
3,994,481 |
6,179,981 |
3,551,559 |
||||
|
Non-GAAP adjusted EBITDA per stock |
$ (0.21) |
$ (0.55) |
$ (1.10) |
$ (1.61) |
||||
About LabStyle Innovations
LabStyle Innovations Corp. (OTCQB:DRIO) develops and commercializes patented technology providing consumers with laboratory-testing capabilities using smart mobile devices. LabStyle’s flagship product is the Dario™ Diabetes Management Solution. Dario™ received CE mark certification in September 2013 and began a world rollout in select countries in December 2013. LabStyle filed a Premarket Notification Application, also known as a 510(k), with the US Food and Drug Administration (FDA) for the Dario™ smart meter (Dario™ Blood Glucose Monitoring System) in December 2013. LabStyle is pursuing patent applications in multiple areas covering the specific processes related to blood glucose level measurement as well as more general methods of rapid tests of body fluids using mobile devices and cloud-based services. For more information: www.mydario.com and http://mydario.investorroom.com.
Cautionary Note Regarding Forward-Looking Statements
This news release and the statements of representatives and partners of LabStyle Innovations Corp. (the “Company”) related thereto contains or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “plan,” “project,” “potential,” “seek,” “may,” “will,” “expect,” “believe,” “anticipate,” “intend,” “could,” “estimate” or “continue” are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company’s actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company’s results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company’s actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company’s filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company’s commercial and regulatory plans for Dario™ as described herein) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
LABSTYLE INNOVATIONS CORP. – CONSOLIDATED BALANCE SHEETS
U.S. dollars in thousands
|
September 30, |
December 31, |
|||
|
2014 |
2013 |
|||
|
Unaudited |
||||
|
ASSETS |
||||
|
CURRENT ASSETS: |
||||
|
Cash and cash equivalents |
$ 4,170 |
$ 2,263 |
||
|
Restricted cash |
– |
38 |
||
|
Short-term bank deposits |
87 |
154 |
||
|
Inventories |
109 |
– |
||
|
Other accounts receivable and prepaid expenses |
362 |
475 |
||
|
Total current assets |
4,728 |
2,930 |
||
|
LEASE DEPOSIT |
48 |
41 |
||
|
PROPERTY AND EQUIPMENT, NET |
1,226 |
1,145 |
||
|
Total assets |
$ 6,002 |
$ 4,116 |
LABSTYLE INNOVATIONS CORP. – CONSOLIDATED BALANCE SHEETS
U.S. dollars in thousands (except stock and stock data)
|
September 30, |
December 31, |
|||
|
2014 |
2013 |
|||
|
Unaudited |
||||
|
LIABILITIES AND STOCKHOLDERS’ DEFICIENCY |
||||
|
CURRENT LIABILITIES: |
||||
|
Trade payables |
$ 1,276 |
$ 586 |
||
|
Other accounts payable and accrued expenses |
818 |
920 |
||
|
Total current liabilities |
2,094 |
1,506 |
||
|
LIABILITY RELATED TO WARRANTS |
3,053 |
2,696 |
||
|
COMMITMENTS AND CONTINGENT LIABILITIES |
||||
|
CONVERTIBLE PREFERRED SHARES: |
||||
|
Series A Preferred Stock of $0.0001 par value – Authorized: 60,000 shares at September 30, 2014 (unaudited) and December 31, 2013; Issued and Outstanding: 42,350 shares at September 30, 2014 (unaudited); Aggregate liquidation preference of $4,235 at September 30, 2014 (unaudited) |
5,781 |
– |
||
|
STOCKHOLDERS’ DEFICIENCY: |
||||
|
Common Stock of $0.0001 par value – Authorized: 80,000,000 and 45,000,000 shares at September 30, 2014 (unaudited) and December 31, 2013, respectively; Issued and Outstanding: 15,905,871 and 4,014,381 shares at September 30, 2014 (unaudited) and December 31, 2013, respectively |
2 |
*) |
||
|
Preferred Stock of $0.0001 par value – Authorized: 4,940,000 and 5,000,000 shares at September 30, 2014 (unaudited) and December 31, 2013, respectively; Issued and Outstanding: none at September 30, 2014 (unaudited) and December 31, 2013 |
– |
– |
||
|
Additional paid-in capital |
27,646 |
19,917 |
||
|
Accumulated deficit |
(32,574) |
(20,003) |
||
|
Total stockholders’ deficiency |
(4,926) |
(86) |
||
|
Total liabilities and stockholders’ deficiency |
$ 6,002 |
$ 4,116 |
LABSTYLE INNOVATIONS CORP. – CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
U.S. dollars in thousands (except stock and stock data)
|
Three months ended September 30, |
Nine months ended September 30, |
||||||||
|
2014 |
2013 |
2014 |
2013 |
||||||
|
Unaudited |
Unaudited |
||||||||
|
Revenues |
$ – |
$ – |
$ – |
$ – |
|||||
|
Ramp up of manufacturing costs |
585 |
– |
1,611 |
– |
|||||
|
Gross loss |
585 |
– |
1,611 |
– |
|||||
|
Operating expenses: |
|||||||||
|
Research and development |
$ 769 |
$ 1,078 |
$ 3,209 |
$ 3,169 |
|||||
|
Marketing and pre-production costs |
252 |
763 |
911 |
1,924 |
|||||
|
General and administrative |
901 |
1,397 |
3,047 |
4,817 |
|||||
|
Total operating expenses |
1,922 |
3,238 |
7,167 |
9,910 |
|||||
|
Operating loss |
2,507 |
3,238 |
8,778 |
9,910 |
|||||
|
Financial expenses (income), net: |
|||||||||
|
Revaluation of warrants |
(2,606) |
192 |
(3,144) |
3,992 |
|||||
|
Other financial expense |
3,176 |
41 |
3,681 |
83 |
|||||
|
Total financial expenses, net |
570 |
233 |
537 |
4,075 |
|||||
|
Net loss |
$ 3,077 |
$ 3,471 |
$ 9,315 |
$ 13,985 |
|||||
|
Deemed dividend related to exchange agreement (Note 4a) |
279 |
– |
279 |
– |
|||||
|
Deemed dividend related to Series A Preferred Stock (Note 4b) |
2,977 |
– |
2,977 |
– |
|||||
|
Net loss attributable to holders of Common Stock |
$ 6,333 |
$ 3,471 |
$ 12,571 |
$ 13,985 |
|||||
|
Net loss per share |
|||||||||
|
Basic loss per share |
$ (0.66) |
$ (0.85) |
$ (2.03) |
$ (3.95) |
|||||
|
Weighted average number of Common Stock used in computing basic net loss per share |
9,610,160 |
3,994,481 |
6,179,981 |
3,551,559 |
|||||
|
Diluted loss per share |
$ (0.66) |
$ (0.85) |
$ (2.23) |
$ (3.95) |
|||||
|
Weighted average number of Common Stock used in computing diluted net loss per share |
9,610,160 |
3,994,481 |
6,194,418 |
3,551,559 |
|||||
|
Contacts: |
|
|
Press |
Investor Relations |
|
Brenda Zeitlin LabStyle Innovations |
Book and Company Inc. 1 212 490 9095 |
|
1 800 896 9062 |
|
|
Brenda@mydario.com |